| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1045209097 |
| P356 | DOI | 10.1038/7391 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/7391 |
| P698 | PubMed publication ID | 10202927 |
| P2093 | author name string | Frank DW | |
| Sawa T | |||
| Kurahashi K | |||
| Ohara M | |||
| Gropper MA | |||
| Wiener-Kronish JP | |||
| Yahr TL | |||
| P2860 | cites work | The Yersinia Yop virulon: LcrV is required for extrusion of the translocators YopB and YopD. | Q24520677 |
| Differential effects of deletions in lcrV on secretion of V antigen, regulation of the low-Ca2+ response, and virulence of Yersinia pestis | Q24673488 | ||
| Exoenzyme S of Pseudomonas aeruginosa is secreted by a type III pathway | Q28492720 | ||
| Escherichia-Pseudomonas shuttle vectors derived from pUC18/19 | Q29615287 | ||
| The Yersinia deadly kiss. | Q33738622 | ||
| In vitro cellular toxicity predicts Pseudomonas aeruginosa virulence in lung infections | Q33756310 | ||
| Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide | Q34539663 | ||
| Exoenzyme S of Pseudomonas aeruginosa ADP-ribosylates the intermediate filament protein vimentin | Q35093210 | ||
| Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague | Q35426559 | ||
| Suppression of cytokines in mice by protein A-V antigen fusion peptide and restoration of synthesis by active immunization. | Q35429159 | ||
| Recombinant V antigen protects mice against pneumonic and bubonic plague caused by F1-capsule-positive and -negative strains of Yersinia pestis | Q35528592 | ||
| Ecto-ADP-ribosyltransferase activity of Pseudomonas aeruginosa exoenzyme S | Q35553139 | ||
| Transcriptional analysis of the Pseudomonas aeruginosa exoenzyme S structural gene | Q35580149 | ||
| Genetic relationship between the 53- and 49-kilodalton forms of exoenzyme S from Pseudomonas aeruginosa. | Q35603442 | ||
| Identification of type III secreted products of the Pseudomonas aeruginosa exoenzyme S regulon | Q35632593 | ||
| ExoY, an adenylate cyclase secreted by the Pseudomonas aeruginosa type III system | Q36809802 | ||
| ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury | Q41095866 | ||
| The Yersinia Yop virulon: a bacterial system for subverting eukaryotic cells | Q41390851 | ||
| Type III secretion systems: machines to deliver bacterial proteins into eukaryotic cells? | Q41462606 | ||
| Functional conservation of the effector protein translocators PopB/YopB and PopD/YopD of Pseudomonas aeruginosa and Yersinia pseudotuberculosis | Q41484833 | ||
| V antigen of Yersinia pestis inhibits neutrophil chemotaxis | Q41485922 | ||
| The exoenzyme S regulon of Pseudomonas aeruginosa | Q41487139 | ||
| Intracellular targeting of exoenzyme S of Pseudomonas aeruginosa via type III-dependent translocation induces phagocytosis resistance, cytotoxicity and disruption of actin microfilaments | Q41487515 | ||
| PepA, a secreted protein of Pseudomonas aeruginosa, is necessary for cytotoxicity and virulence | Q46092317 | ||
| Allelic exchange in Pseudomonas aeruginosa using novel ColE1-type vectors and a family of cassettes containing a portable oriT and the counter-selectable Bacillus subtilis sacB marker | Q68129217 | ||
| Removal of endotoxin from protein solutions by phase separation using Triton X-114 | Q68480102 | ||
| Pseudomonas aeruginosa exoenzyme S ADP-ribosylates Ras at multiple sites | Q74358754 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunization | Q1415366 |
| intoxication | Q18621601 | ||
| passive immunization | Q73525231 | ||
| P304 | page(s) | 392-398 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury | |
| P478 | volume | 5 |
| Q42581042 | A C-terminal domain targets the Pseudomonas aeruginosa cytotoxin ExoU to the plasma membrane of host cells |
| Q64106013 | A Live Vaccine Delivering PcrV through the Type III Secretion System Protects against Pseudomonas aeruginosa |
| Q38940907 | A multifunctional bispecific antibody protects against Pseudomonas aeruginosa |
| Q30408273 | A novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models |
| Q33896093 | A secreted regulatory protein couples transcription to the secretory activity of the Pseudomonas aeruginosa type III secretion system |
| Q33526200 | Activation of ExoU phospholipase activity requires specific C-terminal regions |
| Q34192652 | Activation of the Pseudomonas aeruginosa AlgU regulon through mucA mutation inhibits cyclic AMP/Vfr signaling. |
| Q39655427 | Activation of the Pseudomonas aeruginosa type III secretion system requires an intact pyruvate dehydrogenase aceAB operon |
| Q40406147 | Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system. |
| Q28492911 | An adenylate cyclase-controlled signaling network regulates Pseudomonas aeruginosa virulence in a mouse model of acute pneumonia |
| Q42906503 | An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity |
| Q25256862 | An indirect enzyme-linked immunosorbent assay for rapid and quantitative assessment of Type III virulence phenotypes of Pseudomonas aeruginosa isolates |
| Q33836925 | Anti-PcrV antibody in cystic fibrosis: a novel approach targeting Pseudomonas aeruginosa airway infection |
| Q41380601 | Anti-PcrV antibody strategies against virulent Pseudomonas aeruginosa |
| Q40693200 | Apoptosis induced by Pseudomonas aeruginosa in antigen presenting cells is diminished by genetic modification with CD40 ligand |
| Q36284542 | Application of vaccine technology to prevention of Pseudomonas aeruginosa infections. |
| Q38366322 | Approaches targeting the type III secretion system to treat or prevent bacterial infections |
| Q27013824 | Association between Pseudomonas aeruginosa type III secretion, antibiotic resistance, and clinical outcome: a review |
| Q36088671 | Bioinformatics, genomics and evolution of non-flagellar type-III secretion systems: a Darwinian perspective |
| Q38809322 | Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature |
| Q29346817 | Characterization of ExsA and of ExsA-dependent promoters required for expression of the Pseudomonas aeruginosa type III secretion system. |
| Q43422418 | Characterization of molten globule PopB in absence and presence of its chaperone PcrH. |
| Q34491552 | Clinical significance of microbial infection and adaptation in cystic fibrosis |
| Q30453226 | Construction and characterization of a live, attenuated aroA deletion mutant of Pseudomonas aeruginosa as a candidate intranasal vaccine |
| Q35071514 | Control of effector export by the Pseudomonas aeruginosa type III secretion proteins PcrG and PcrV. |
| Q35783560 | Development of in vitro correlate assays of immunity to infection with Yersinia pestis. |
| Q33601814 | Direct neutralization of type III effector translocation by the variable region of a monoclonal antibody to Yersinia pestis LcrV |
| Q37510611 | Diversity of virulence phenotypes among type III secretion negative Pseudomonas aeruginosa clinical isolates |
| Q33553144 | Dual-function vaccine for Pseudomonas aeruginosa: characterization of chimeric exotoxin A-pilin protein |
| Q34041909 | Early immune response to the components of the type III system of Pseudomonas aeruginosa in children with cystic fibrosis |
| Q47989907 | Effect of lung-protective ventilation on severe Pseudomonas aeruginosa pneumonia and sepsis in rats |
| Q44326703 | Effects of Cl2MDP-encapsulating liposomes in a murine model of Pseudomonas aeruginosa-induced sepsis |
| Q24797978 | Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosa-induced acute lung injury in a rat model |
| Q40267074 | Efficacy comparison of adjuvants in PcrV vaccine against Pseudomonas aeruginosa pneumonia |
| Q33965276 | Efficient isolation of Pseudomonas aeruginosa type III secretion translocators and assembly of heteromeric transmembrane pores in model membranes |
| Q40860257 | Epidemiological analysis of serum anti-Pseudomonas aeruginosa PcrV titers in adults |
| Q90186755 | Epidemiological survey of serum titers from adults against various Gram-negative bacterial V-antigens |
| Q34019954 | Establishment of Pseudomonas aeruginosa infection: lessons from a versatile opportunist |
| Q36163142 | Examining the role of actin-plasma membrane association in Pseudomonas aeruginosa infection and type III secretion translocation in migratory T24 epithelial cells |
| Q41476159 | Exoenzyme T of Pseudomonas aeruginosa elicits cytotoxicity without interfering with Ras signal transduction |
| Q39517996 | Expression of ExsA in trans confers type III secretion system-dependent cytotoxicity on noncytotoxic Pseudomonas aeruginosa cystic fibrosis isolates |
| Q28492983 | ExsE, a secreted regulator of type III secretion genes in Pseudomonas aeruginosa |
| Q90213083 | Fitting Pieces into the Puzzle of Pseudomonas aeruginosa Type III Secretion System Gene Expression |
| Q44544638 | For Pseudomonas aeruginosa, stealth is no longer enough |
| Q29346800 | Functional domains of ExsA, the transcriptional activator of the Pseudomonas aeruginosa type III secretion system |
| Q39192014 | Functional insights into the Shigella type III needle tip IpaD in secretion control and cell contact. |
| Q36029891 | High Throughput Combinatorial Formatting of PcrV Nanobodies for Efficient Potency Improvement |
| Q33778441 | Hijacking of the pleiotropic cytokine interferon-γ by the type III secretion system of Yersinia pestis |
| Q30423024 | Identification of broadly protective human antibodies to Pseudomonas aeruginosa exopolysaccharide Psl by phenotypic screening |
| Q35749810 | Immunization with 3-oxododecanoyl-L-homoserine lactone-r-PcrV conjugate enhances survival of mice against lethal burn infections caused by Pseudomonas aeruginosa. |
| Q45174642 | Immunization with Bivalent Flagellin Protects Mice against Fatal Pseudomonas aeruginosa Pneumonia. |
| Q54211649 | Immunological blocking of spermidine-mediated host-pathogen communication provides effective control against Pseudomonas aeruginosa infection. |
| Q27300857 | In the absence of effector proteins, the Pseudomonas aeruginosa type three secretion system needle tip complex contributes to lung injury and systemic inflammatory responses |
| Q42215692 | In vitro assays to monitor the activity of Pseudomonas aeruginosa Type III secreted proteins |
| Q44547313 | In vivo phospholipase activity of the Pseudomonas aeruginosa cytotoxin ExoU and protection of mammalian cells with phospholipase A2 inhibitors |
| Q36571859 | Inhibition of Pseudomonas aeruginosa ExsA DNA-Binding Activity by N-Hydroxybenzimidazoles |
| Q36422470 | Innate Immune Signaling Activated by MDR Bacteria in the Airway |
| Q41471377 | Interactions of the type III secretion pathway proteins LcrV and LcrG from Yersinia pestis are mediated by coiled-coil domains. |
| Q35159314 | Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen) |
| Q27318150 | Intoxication of host cells by the T3SS phospholipase ExoU: PI(4,5)P2-associated, cytoskeletal collapse and late phase membrane blebbing |
| Q38783043 | Investigational drugs in phase I and phase II clincial trials for the treatment of hospital-acquired pneumonia. |
| Q33946882 | LcrV plague vaccine with altered immunomodulatory properties |
| Q36540610 | Limiting too much of a good thing: a negative feedback mechanism prevents unregulated translocation of type III effector proteins. |
| Q37823656 | Membrane targeting and pore formation by the type III secretion system translocon |
| Q37124570 | Metabolic regulation of type III secretion gene expression in Pseudomonas aeruginosa. |
| Q37171635 | Metastatic MTLn3 and non-metastatic MTC adenocarcinoma cells can be differentiated by Pseudomonas aeruginosa |
| Q28492629 | Modified needle-tip PcrV proteins reveal distinct phenotypes relevant to the control of type III secretion and intoxication by Pseudomonas aeruginosa |
| Q30431366 | Multi-Functional Characteristics of the Pseudomonas aeruginosa Type III Needle-Tip Protein, PcrV; Comparison to Orthologs in other Gram-negative Bacteria |
| Q33996557 | Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU. |
| Q64449315 | Multivalent DNA vaccine protects mice against pulmonary infection caused by Pseudomonas aeruginosa |
| Q41734690 | Novel lipid-based hollow-porous microparticles as a platform for immunoglobulin delivery to the respiratory tract |
| Q33811627 | Novel strategies to combat bacterial virulence |
| Q39927824 | Oligomerization of type III secretion proteins PopB and PopD precedes pore formation in Pseudomonas |
| Q35943272 | Orientation of Pseudomonas aeruginosa ExsA monomers bound to promoter DNA and base-specific contacts with the P(exoT) promoter |
| Q57481190 | PLGA-encapsulation of the Pseudomonas aeruginosa PopB vaccine antigen improves Th17 responses and confers protection against experimental acute pneumonia |
| Q92356336 | Particulate matter disrupts airway epithelial barrier via oxidative stress to promote Pseudomonas aeruginosa infection |
| Q36032639 | Pathogen-host interactions in Pseudomonas aeruginosa pneumonia |
| Q33853738 | Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia |
| Q54326043 | Pathophysiology of Escherichia coli ventilator-associated pneumonia: implication of highly virulent extraintestinal pathogenic strains. |
| Q43472217 | PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice |
| Q24548633 | PcrV immunization enhances survival of burned Pseudomonas aeruginosa-infected mice |
| Q34013649 | Perivascular fluid cuffs decrease lung compliance by increasing tissue resistance. |
| Q36889954 | Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia |
| Q37825920 | Pertussis: a matter of immune modulation |
| Q33812082 | Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV - implications for anti-PcrV immunotherapy |
| Q40813368 | Pore-forming activity of type III system-secreted proteins leads to oncosis of Pseudomonas aeruginosa-infected macrophages |
| Q40219808 | Prediction of vaccine candidates against Pseudomonas aeruginosa: An integrated genomics and proteomics approach |
| Q37364299 | Prevalence of type III secretion protein exoenzymes and antimicrobial susceptibility patterns from bloodstream isolates of patients with Pseudomonas aeruginosa bacteremia |
| Q34007482 | Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa |
| Q30453151 | Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant |
| Q33822579 | Protective Efficacy of the Trivalent Pseudomonas aeruginosa Vaccine Candidate PcrV-OprI-Hcp1 in Murine Pneumonia and Burn Models |
| Q33553646 | Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection |
| Q37910755 | Protein Secretion Systems in Pseudomonas aeruginosa: An Essay on Diversity, Evolution, and Function |
| Q28492902 | Protein binding between PcrG-PcrV and PcrH-PopB/PopD encoded by the pcrGVH-popBD operon of the Pseudomonas aeruginosa type III secretion system |
| Q36487854 | Pseudomonas aeruginosa Bacteremic Patients Exhibit Nonprotective Antibody Titers Against Therapeutic Antibody Targets PcrV and Psl Exopolysaccharide |
| Q33180176 | Pseudomonas aeruginosa cystic fibrosis isolates induce rapid, type III secretion-dependent, but ExoU-independent, oncosis of macrophages and polymorphonuclear neutrophils |
| Q33178932 | Pseudomonas aeruginosa induces type-III-secretion-mediated apoptosis of macrophages and epithelial cells |
| Q36195845 | Pseudomonas aeruginosa pilin activates the inflammasome |
| Q54221826 | Pseudomonas aeruginosa type-3 secretion system dampens host defense by exploiting the NLRC4-coupled inflammasome. |
| Q37358382 | Pseudomonas aeruginosa virulence and therapy: evolving translational strategies |
| Q43414816 | Pseudomonas aeruginosa-specific IgG1 and IgG2 subclasses in enhancement of pulmonary clearance following passive immunisation in the rat. |
| Q35710136 | Pseudomonas immunotherapy: a historical overview |
| Q44870495 | Pseudomonas: global bacteria |
| Q64093242 | Rational Design of a Chimeric Derivative of PcrV as a Subunit Vaccine Against |
| Q37937369 | Recent developments for Pseudomonas vaccines |
| Q28493109 | Regulatory role of PopN and its interacting partners in type III secretion of Pseudomonas aeruginosa |
| Q37624028 | Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung |
| Q41307994 | Role of host cell polarity and leading edge properties in Pseudomonas type III secretion |
| Q39023459 | Role of integrin alphav beta6 in acute lung injury induced by Pseudomonas aeruginosa |
| Q34004144 | RpmA is required for nonopsonic phagocytosis of Pseudomonas aeruginosa |
| Q35626010 | Secretion of Flagellar Proteins by the Pseudomonas aeruginosa Type III Secretion-Injectisome System |
| Q34297881 | Self-association is required for occupation of adjacent binding sites in Pseudomonas aeruginosa type III secretion system promoters. |
| Q34006116 | Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus |
| Q38006509 | Surface organelles assembled by secretion systems of Gram-negative bacteria: diversity in structure and function |
| Q39741669 | Synergistic protection of mice against plague with monoclonal antibodies specific for the F1 and V antigens of Yersinia pestis |
| Q35108903 | T helper cell subsets specific for Pseudomonas aeruginosa in healthy individuals and patients with cystic fibrosis |
| Q24805246 | TLR4 signaling is essential for survival in acute lung injury induced by virulent Pseudomonas aeruginosa secreting type III secretory toxins |
| Q92557925 | Tanshinones: First-in-Class Inhibitors of the Biogenesis of the Type 3 Secretion System Needle of Pseudomonas aeruginosa for Antibiotic Therapy |
| Q38167861 | Targeting the type III secretion system to treat bacterial infections. |
| Q34313640 | Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia |
| Q37051598 | The ADP-ribosylating toxin, AexT, from Aeromonas salmonicida subsp. salmonicida is translocated via a type III secretion pathway |
| Q35050399 | The Type III secretion system of Gram-negative bacteria: a potential therapeutic target? |
| Q41195095 | The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes |
| Q34478058 | The ability of virulence factor expression by Pseudomonas aeruginosa to predict clinical disease in hospitalized patients |
| Q35915815 | The influence of human respiratory epithelia on Pseudomonas aeruginosa gene expression |
| Q34711734 | The molecular mechanism of acute lung injury caused by Pseudomonas aeruginosa: from bacterial pathogenesis to host response |
| Q40601021 | The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa |
| Q40182759 | The salicylidene acylhydrazide INP0341 attenuates Pseudomonas aeruginosa virulence in vitro and in vivo |
| Q41475300 | The type III pseudomonal exotoxin U activates the c-Jun NH2-terminal kinase pathway and increases human epithelial interleukin-8 production |
| Q37397923 | The type III secretion system of Pseudomonas aeruginosa: infection by injection |
| Q34011259 | The type III secretion system tip complex and translocon. |
| Q64098572 | Thinking Outside the Bug: Molecular Targets and Strategies to Overcome Antibiotic Resistance |
| Q34681186 | Transcriptional induction of the Pseudomonas aeruginosa type III secretion system by low Ca2+ and host cell contact proceeds through two distinct signaling pathways |
| Q35947303 | Translocation of ExsE into Chinese hamster ovary cells is required for transcriptional induction of the Pseudomonas aeruginosa type III secretion system. |
| Q48382561 | Two B cell epitopes of HIV-1 Tat protein have limited antigenic polymorphism in geographically diverse HIV-1 strains |
| Q34834090 | Type II secretion system of Pseudomonas aeruginosa: in vivo evidence of a significant role in death due to lung infection |
| Q37597434 | Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis |
| Q24793790 | Type III secretion proteins PcrV and PcrG from Pseudomonas aeruginosa form a 1:1 complex through high affinity interactions |
| Q33955524 | Type III secretion: a bacterial device for close combat with cells of their eukaryotic host |
| Q37516904 | Update on the treatment of Pseudomonas aeruginosa pneumonia |
| Q24682662 | Use of the Galleria mellonella Caterpillar as a Model Host To Study the Role of the Type III Secretion System in Pseudomonas aeruginosa Pathogenesis |
| Q37156677 | V-antigen genotype and phenotype analyses of clinical isolates of Pseudomonas aeruginosa |
| Q27008415 | V-antigen homologs in pathogenic gram-negative bacteria |
| Q28266964 | Vaccines and immunotherapy against Pseudomonas aeruginosa |
| Q26852817 | Vaccines for Pseudomonas aeruginosa: a long and winding road |
| Q42855404 | Ventilator-associated pneumonia caused by Pseudomonas aeruginosa: cap your needles! |
| Q90663260 | Virulence-Inhibiting Herbal Compound Falcarindiol Significantly Reduced Mortality in Mice Infected with Pseudomonas aeruginosa |
| Q36371199 | Yersinia V-antigen exploits toll-like receptor 2 and CD14 for interleukin 10-mediated immunosuppression |
Search more.